The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older Recommendation is based on pre-clinical and epidemiological data showing that the JN.1-adapted monovalent COVID-19 vaccine generates an improved immune response against multiple JN.1 sublineages Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission NEW YORK and MAINZ, Germany, June 27, 2024 — Pfizer Inc. ...